2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC). (September 2015) - Martens, U.M.; Wessendorf, S.; Knorrenschild, J. Riera; Buechner-Steudel, P.; Florschuetz, A.; Atzpodien, J.; Greeve, J.; Kanzler, S.; Ettrich, T.; Lindig, U.; Egger, M.; Hebart, H.; et al.